🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody

Found 29 matching trials

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

PHASE3

This randomized, open-label study will evaluate the efficacy and safety of ...

Status

Completed

Location

University of California San Diego

Start Date

2015-07-20

Trial ID

NCT02409342

Treatments Being Tested

Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody Carboplatin Cisplatin Gemcitabine Pemetrexed

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

PHASE2

This multicenter, open-label, randomized study will evaluate the efficacy a...

Status

Completed

Location

Arizona Oncology Associates, PC - HOPE

Start Date

2013-08-06

Trial ID

NCT01903993

Treatments Being Tested

Docetaxel Atezolizumab

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

PHASE1

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation stu...

Status

Completed

Location

HonorHealth Research Institute ? Bisgrove

Start Date

2017-12-21

Trial ID

NCT03289962

Treatments Being Tested

Autogene cevumeran Atezolizumab

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

PHASE1

This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-ex...

Status

Completed

Location

UCLA

Start Date

2012-08-13

Trial ID

NCT01656642

Treatments Being Tested

Atezolizumab Cobimetinib Vemurafenib

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

PHASE3

This randomized, Phase I/III, multicenter, double-blinded, placebo-controll...

Status

Completed

Location

Florida Cancer Specialists - Fort Myers (Broadway)

Start Date

2016-06-07

Trial ID

NCT02763579

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Carboplatin Etoposide Placebo

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

PHASE3

This is a randomized, double-blinded study designed to evaluate the efficac...

Status

Completed

Location

Arizona Oncology

Start Date

2018-04-24

Trial ID

NCT03456063

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Placebo Comparator Nab-paclitaxel Pemetrexed Carboplatin Cisplatin Gemcitabine

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

PHASE3

This randomized Phase III, multicenter, open-label study designed to evalua...

Status

Completed

Location

Highlands Oncology Group

Start Date

2015-04-16

Trial ID

NCT02367781

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Carboplatin Nab-Paclitaxel Pemetrexed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

PHASE2

This multicenter, randomized, open-label study will evaluate the efficacy, ...

Status

Completed

Location

HonorHealth Research Institute - Bisgrove

Start Date

2014-01-08

Trial ID

NCT01984242

Treatments Being Tested

Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody Bevacizumab Sunitinib

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

PHASE3

This is a global Phase III, double-blind, randomized, placebo-controlled st...

Status

Completed

Location

Stanford University Medical Center

Start Date

2017-07-24

Trial ID

NCT03197935

Treatments Being Tested

Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody Placebo Nab-paclitaxel Doxorubicin Cyclophosphamide Filgrastim Pegfilgrastim

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

PHASE3

This is a Phase III, global, multicenter, open-label, two-arm, randomized, ...

Status

Completed

Location

Georgetown University Medical Center Lombardi Cancer Center

Start Date

2015-01-13

Trial ID

NCT02302807

Treatments Being Tested

Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody Docetaxel Paclitaxel Vinflunine

Previous Next